Achieving vaccine equity: challenges and opportunities of multi-modality manufacturing

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Achieving vaccine equity: challenges and opportunities of multi-modality manufacturing

With the rising popularity of nucleic acid-based vaccines, manufacturers have more choices than ever for their vaccine platforms. What essential steps can ensure smooth adoption of these new technologies around the world, including in developing countries?

In this presentation, we address the challenges and opportunities for three vaccine modalities: viral vector (AAV), pDNA, and mRNA.

Join this webinar to learn more about:

Why mRNA vaccines are faster to produce than traditional vaccine platforms
The challenges faced by multimodality manufacturers
Considerations for manufacturing with smaller volumes
How digitalization supports manufacturing

Katarina Stenklo

Enterprise Solutions Commercial Activation Leader at Cytiva

Katarina Stenklo holds a licentiate degree in biochemistry and have over 20 years of industry experience. She currently works for Cytiva in the Manufacturing capacity solutions business unit. She has extensive expertise in developing end-to-end manufacturing solutions that includes process workflows, process equipment, automation, consumables, and facilities. Her focus over the last few years has been developing and designing solutions for the manufacture of new product modalities such as viral vectors, plasmids, and mRNA therapies.